Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer

Cancer

Volumn 116, Issue 22, 2010, Pages 5226-5234

  Cooperberg, Matthew R ^a   Vickers, Andrew J ^b   Broering, Jeanette M ^a   Carroll, Peter R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Cancer of the Prostate Strategic Urologic Research Endeavor; comparative effectiveness; hormone therapy; prostate neoplasms; radiation; surgery

Indexed keywords

ANTIANDROGEN; FLUTAMIDE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURGERY; COMPARATIVE STUDY; CONFIDENCE INTERVAL; EXTERNAL BEAM RADIOTHERAPY; GLEASON SCORE; HAZARD RATIO; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORTALITY; NOMOGRAM; OUTCOMES RESEARCH; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; REGRESSION ANALYSIS; RISK ASSESSMENT; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

AGED; ANDROGEN ANTAGONISTS; HUMANS; MALE; MIDDLE AGED; PROSTATECTOMY; PROSTATIC NEOPLASMS; RISK; TREATMENT OUTCOME;

EID: 78449267553     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25456     Document Type: Article

References (42)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ,. Cancer statistics, 2009. CA Cancer J Clin. 2009; 59: 225-249.
2. Lu-Yao GL, Albertsen PC, Moore DF, et al. Outcomes of localized prostate cancer following conservative management. JAMA. 2009; 302: 1202-1209.
3. Wei JT, Dunn RL, Sandler HM, et al. Comprehensive comparison of health-related quality of life after contemporary therapies for localized prostate cancer. J Clin Oncol. 2002; 20: 557-566.
4. Wilt TJ, MacDonald R, Rutks I, Shamliyan TA, Taylor BC, Kane RL,. Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer. Ann Intern Med. 2008; 148: 435-448.
5. Thompson I, Thrasher JB, Aus G, et al. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol. 2007; 177: 2106-2131.
6. Cooperberg MR, Grossfeld GD, Lubeck DP, Carroll PR,. National practice patterns and time trends in androgen ablation for localized prostate cancer. J Natl Cancer Inst. 2003; 95: 981-989.
7. Shahinian VB, Kuo YF, Freeman JL, Orihuela E, Goodwin JS,. Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer. 2005; 103: 1615-1624.
8. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC,. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999; 281: 1591-1597.
9. Cookson MS, Aus G, Burnett AL, et al. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol. 2007; 177: 540-545.
10. Marr PL, Elkin EP, Arredondo SA, Broering JM, DuChane J, Carroll PR,. Comorbidity and primary treatment for localized prostate cancer: data from CaPSURE. J Urol. 2006; 175: 1326-1331.
11. Lubeck DP, Litwin MS, Henning JM, et al. The CaPSURE database: a methodology for clinical practice and research in prostate cancer. CaPSURE Research Panel. Cancer of the Prostate Strategic Urologic Research Endeavor. Urology. 1996; 48: 773-777.
12. Cooperberg MR, Broering JM, Litwin MS, et al. The contemporary management of prostate cancer in the United States: lessons from the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE), a national disease registry. J Urol. 2004; 171: 1393-1401.
13. Kattan MW, Eastham JA, Stapleton AM, Wheeler TM, Scardino PT,. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst. 1998; 90: 766-771.
14. Graefen M, Karakiewicz PI, Cagiannos I, et al. International validation of a preoperative nomogram for prostate cancer recurrence after radical prostatectomy. J Clin Oncol. 2002; 20: 3206-3212.
15. Greene KL, Meng MV, Elkin EP, et al. Validation of the Kattan preoperative nomogram for prostate cancer recurrence using a community based cohort: results from Cancer of the Prostate Strategic Urological Research Endeavor (CaPSURE). J Urol. 2004; 171 (6 pt 1): 2255-2259.
16. Zhao KH, Hernandez DJ, Han M, Humphreys EB, Mangold LA, Partin AW,. External validation of University of California, San Francisco, Cancer of the Prostate Risk Assessment score. Urology. 2008; 72: 396-400.
17. Cooperberg MR, Pasta DJ, Elkin EP, et al. The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J Urol. 2005; 173: 1938-1942.
18. Cooperberg MR, Freedland SJ, Pasta DJ, et al. Multiinstitutional validation of the UCSF Cancer of the Prostate Risk Assessment for prediction of recurrence after radical prostatectomy. Cancer. 2006; 107: 2384-2391.
19. May M, Knoll N, Siegsmund M, et al. Validity of the CAPRA score to predict biochemical recurrence-free survival after radical prostatectomy. Results from a European multicenter survey of 1296 patients. J Urol. 2007; 178: 1957-1962.
20. Cooperberg MR, Broering JM, Carroll PR,. Risk assessment for prostate cancer metastasis and mortality at the time of diagnosis. J Natl Cancer Inst. 2009; 101: 878-887.
21. Pocock SJ, Clayton TC, Altman DG,. Survival plots of time-to-event outcomes in clinical trials: good practice and pitfalls. Lancet. 2002; 359: 1686-1689.
22. Fine JP, Gray RJ,. A proportional hazards model for the subdistribution of competing risk. J Am Stat Assoc. 1999; 94: 496-509.
23. The Center for Evaluative Clinical Sciences at Dartmouth Medical School. The Quality of Medical Care in the United States. Hanover, NH: American Hospital Association; 1999.
24. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS,. Determinants of androgen deprivation therapy use for prostate cancer: role of the urologist. J Natl Cancer Inst. 2006; 98: 839-845.
25. Cooperberg MR, Broering JM, Carroll PR,. Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol. 2010; 28: 1117-1123.
26. Cooperberg MR, Cowan J, Broering JM, Carroll PR,. High-risk prostate cancer in the United States, 1990-2007. World J Urol. 2008; 26: 211-218.
27. Yossepowitch O, Eastham JA,. Radical prostatectomy for high-risk prostate cancer. World J Urol. 2008; 26: 219-224.
28. Institute of Medicine Committee on Comparative Effectiveness Research Prioritization. Initial National Priorities for Comparative Effectiveness Research. Washington, DC: National Academy Press; 2009.
29. Bill-Axelson A, Holmberg L, Filen F, et al. Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. J Natl Cancer Inst. 2008; 100: 1144-1154.
30. Iversen P, Madsen PO, Corle DK,. Radical prostatectomy versus expectant treatment for early carcinoma of the prostate. Twenty-three year follow-up of a prospective randomized study. Scand J Urol Nephrol. 1995; 172 (suppl): 65-72.
31. Widmark A, Klepp O, Solberg A, et al. Scandinavian Prostate Cancer Group Study 7; Swedish Association for Urological Oncology 3. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet. 2009; 373: 301-308.
32. Wallace K, Fleshner N, Jewett M, Basiuk J, Crook J,. Impact of a multi-disciplinary patient education session on accrual to a difficult clinical trial: the Toronto experience with the surgical prostatectomy versus interstitial radiation intervention trial. J Clin Oncol. 2006; 24: 4158-4162.
33. Wilt TJ, Brawer MK, Barry MJ, et al. The Prostate cancer Intervention Versus Observation Trial: VA/NCI/AHRQ Cooperative Studies Program 407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer. Contemp Clin Trials. 2009; 30: 81-87.
34. Donovan JL, Lane JA, Peters TJ, et al. Development of a complex intervention improved randomization and informed consent in a randomized controlled trial. J Clin Epidemiol. 2009; 62: 29-36.
35. Lu-Yao GL, Albertsen PC, Moore DF, et al. Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA. 2008; 300: 173-181.
36. Wong YN, Mitra N, Hudes G, et al. Survival associated with treatment vs observation of localized prostate cancer in elderly men. JAMA. 2006; 296: 2683-2693.
37. Naik AD, Petersen LA,. The neglected purpose of comparative-effectiveness research. N Engl J Med. 2009; 360: 1929-1931.
38. Agarwal PK, Sadetsky N, Konety BR, Resnick MI, Carroll PR,. Treatment failure after primary and salvage therapy for prostate cancer: likelihood, patterns of care, and outcomes. Cancer. 2008; 112: 307-314.
39. Zelefsky MJ, Eastham JA, Cronin AM, et al. Metastasis after radical prostatectomy or external beam radiotherapy for patients with clinically localized prostate cancer: a comparison of clinical cohorts adjusted for case mix. J Clin Oncol. 2010; 28: 1508-1513.
40. Zietman AL, DeSilvio ML, Slater JD, et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA. 2005; 294: 1233-1239 [erratum in: JAMA. 2008; 299: 898-899].
41. Horwitz EM, Bae K, Hanks GE, et al. Ten-year follow-up of Radiation Therapy Oncology Group Protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol. 2008; 26: 2497-2504.
42. Litwin MS, Greenfield S, Elkin EP, Lubeck DP, Broering JM, Kaplan SH,. Assessment of prognosis with the total illness burden index for prostate cancer. Cancer. 2007; 109: 1777-1783.